<DOC>
	<DOC>NCT00940602</DOC>
	<brief_summary>The primary purpose of this study is to prospectively assess the efficacy and safety of iron chelation therapy with deferasirox compared to placebo in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload.</brief_summary>
	<brief_title>Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Males or females â‰¥ 18 years of age Patients must weigh between 35135 kg MDS low int1 risk as determined by IPSS score and confirmed by bone marrow examination within 6 months prior to study entry Ferritin&gt; 1000 mcg/L at screening History of 15 to 75 PRBC transfusions Anticipated to be transfused at least 8 times annually during the study More than 6 months of cumulative ironchelation therapy (such as daily deferasirox (Exjade) or deferiprone or 5x/week deferosamine). intermittent deferoxamine doses in association with blood transfusions are not exclusionary regardless of duration of such treatment. More than 3 years since patient began receiving regular transfusions (2 units per 8 weeks or 4 units received in a 3 month period). Creatinine clearance &lt; 40 ml/min Serum creatinine &gt;1.5x ULN at screening Significant proteinuria: urinary protein/creatinine ratio &gt;0.5 mg/mg in a non first void urine sample ECOG performance status &gt; 2 Left ventricular ejection fraction &lt; 50% by ECHO History of hospitalization for Congestive Heart Failure Systemic disease that would prevent study treatment (uncontrolled hypertension, cardiovascular renal, hepatic (including ChildPugh Class B and C) or metabolic disease) Hepatitis B or C (HBsAg in the absences or HBsAB or HCV Ab positive with HCV RNA positive) History of HIV positivity by (ELISA or Western blot) Treatment with systemic investigational drug within 4 weeks or topical investigational drug within 7 days of study start ALT or AST &gt; 3.5 x ULN at screening Total bilirubin &gt; 1.5 x ULN at screening Diagnosis of liver cirrhosis Patient participating in another clinical trial or receiving an investigational drug History of another malignancy within the past five years, with the exception of basal skin carcinoma or cervical carcinoma in situ or completely resected colonic polyps carcinoma in situ History of noncompliance with medical regimen, or patients potentially unreliable and/or not cooperative Presence of surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drug Pregnant or intending to become pregnant or breastfeeding patents History of drug or alcohol abuse within the 12 months prior to enrollment. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>TELESTO</keyword>
	<keyword>MDS Study</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Myelodysplastic Syndromes (low-int-1 risk)</keyword>
</DOC>